linsitinib   

GtoPdb Ligand ID: 7423

Synonyms: ASP-7487 | OSI 906 | OSI-906 | OSI906
Compound class: Synthetic organic
Comment: Note that the chemical structure in the PubChem record is for the non-stereo molecule. The INN record specifies stereochemistry as shown in our chemical structure.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 89.33
Molecular weight 421.19
XLogP 4.93
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES Nc1nccn2c1c(nc2C1CC(C1)(C)O)c1ccc2c(c1)nc(cc2)c1ccccc1
Isomeric SMILES Nc1nccn2c1c(nc2[C@@H]1C[C@](C1)(C)O)c1ccc2c(c1)nc(cc2)c1ccccc1
InChI InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+
InChI Key PKCDDUHJAFVJJB-VLZXCDOPSA-N
No information available.
Summary of Clinical Use
Linsitinib is a drug candidate for the treatment of various types of cancer, with trials reaching Phase III. Visit ClinicalTrials.gov to view currently registered drug trials involving this compound.
Mechanism Of Action and Pharmacodynamic Effects
Linsitinib is a dual IGF-1R/insulin receptor (IR) kinase inhibitor. This inhibits IGF-1R-driven tumorigenesis and metastasis [1].